Tang Ren Tong net income increased nearly 20% overseas revenue increased by more than 50%

Securities Times reporter Shinxin Tong Ren Tong (600085) Today's annual report shows that 2010, the company realized operating income of 3.824 billion yuan, an increase of 16.3%, to achieve net profit of 343 million yuan, the year-on-year increase of 19.19%; Earnings per share is 0.659 yuan. In the sales policy, the company continued to adhere to the cash sales, accounts receivable at the quarter of the season to clear zero measures. As sales policy implementation in place, in order to ensure the steady growth of sales revenue on the basis of continuing to achieve the parent company no new accounts receivable.　　During the reporting period, more than 70% of the varieties operated by the marketing branch have achieved steady growth. At the same time, Tongren Tong also continued to strengthen the medical market development, through the development of a brand-specific community training, academic training for the variety to promote specifics. In addition, the company actively participate in a number of provincial and municipal basic drug tender work, to enter the medical market experience.　　Sales in Beijing have increased by more than 20% over a year earlier. Company leading product sales to achieve stable growth, the overall average increase of more than 10%, to maintain a better market share. Two or three line varieties also have good performance, of which 40% of the varieties grow rapidly. 2010, the company realized the main business income of 3.785 billion yuan.　　In the region, the domestic income of 3.455 billion yuan, an increase of 13.08%, overseas areas to achieve business income of 330 million yuan, an increase of 54.58%. In the field of scientific research, 2010, the company five types of new drugs Yu Le capsules in accordance with the supplementary requirements of the Drug Administration to declare the relevant information, is currently preparing to meet the drug Supervision Department on-site inspection. Eight class of new drugs Kun Bao tablets in the year to obtain clinical approval, the second phase of clinical trial work successfully carried out.　　In addition, the research department has completed the research on the testing methods of some export varieties, providing strong support for the export registration of these varieties. In recent years, the price of traditional Chinese medicine raw materials rose in general, Tongren said that will continue to pay close attention to timely changes in accordance with the situation of procurement and storage work; Further play the role of medicinal plant base, do a good job on the reserve of the fine medicinal herbs, in addition, continue to rely on scientific research